Quantcast
Home > Quotes > XENT
XENT

Intersect ENT, Inc. Common Stock (XENT) Quote & Summary Data

$34.35
*  
1.30
3.93%
Get XENT Alerts
*Delayed - data as of Jul. 17, 2018  -  Find a broker to begin trading XENT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    XENT After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 32.90 / $ 34.65
Today's High / Low
$ 34.65 / $ 33
Share Volume
408,483
50 Day Avg. Daily Volume
333,684
Previous Close
$ 33.05
52 Week High / Low
$ 42.95 / $ 26.90
Market Cap
1,035,162,875
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
408,483
50 Day Avg. Daily Volume:
333,684

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.55

Trading Range

The current last sale of $34.35 is 27.70% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 34.65 $ 42.95
 Low: $ 33 $ 26.90

ETFs with XENT as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0.93% iShares U.S. Pharmaceutical ETF (IHE) +5.22 (3.43%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. Our approved products are steroid releasing implants designed to treat the spectrum of needs among patients who are managed by ENT physicians for chronic sinusitis, one of the most prevalent chronic diseases in the United States and one of the most costly conditions for U.S. employers. We are currently marketing our PROPEL® family of products, consisting of PROPEL®, PROPEL® Mini and PROPEL® Contour, which are used following sinus surgery to deliver steroid locally to treat inflammation and improve surgical outcomes. In addition, we received FDA approval in December 2017 for our SINUVA(TM) Sinus Implant, a new targeted approach to treating nasal polyp disease in patients who have had previous ethmoid sinus surgery.  ... More ...  

Risk Grade

Where does XENT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 33
Open Date:
Jul. 17, 2018
Close Price:
$ 34.35
Close Date:
Jul. 17, 2018

Consensus Recommendation

Analyst Info